Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Systemic therapy for advanced hepatocellular carcinoma has expanded at an
unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the …
unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the …
Immunotherapy for metastatic non-small cell lung cancer: therapeutic advances and biomarkers
M Russano, G La Cava, A Cortellini, F Citarella… - Current …, 2023 - mdpi.com
Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and
improved patients' prognosis. Immune checkpoint inhibitors have quickly become standard …
improved patients' prognosis. Immune checkpoint inhibitors have quickly become standard …
Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies
E Blanco, N Silva-Pilipich, A Bocanegra… - British Journal of …, 2024 - nature.com
Background Previous studies have shown that functional systemic immunity is required for
the efficacy of PD-1/PD-L1 blockade immunotherapies in cancer. Hence, systemic …
the efficacy of PD-1/PD-L1 blockade immunotherapies in cancer. Hence, systemic …
Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors
E Blanco, L Chocarro, L Fernández-Rubio… - International Journal of …, 2023 - mdpi.com
Immunotherapies based on immune checkpoint blockade have shown remarkable clinical
outcomes and durable responses in patients with many tumor types. Nevertheless, these …
outcomes and durable responses in patients with many tumor types. Nevertheless, these …
Immune profiling uncovers memory T-cell responses with a Th17 signature in cancer patients with previous SARS-CoV-2 infection followed by mRNA vaccination
M Echaide, I Labiano, M Delgado… - Cancers, 2022 - mdpi.com
Simple Summary Cancer patients are considered a high-risk group for infectious diseases
including COVID-19. The protective effects of vaccination are unclear in oncologic patients …
including COVID-19. The protective effects of vaccination are unclear in oncologic patients …
The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC)
CW Wang, PK Biswas, A Islam, MK Chen, PJ Chueh - Cells, 2024 - mdpi.com
Immunotherapy has emerged as a promising new treatment modality for head and neck
cancer, offering the potential for targeted and effective cancer management. Squamous cell …
cancer, offering the potential for targeted and effective cancer management. Squamous cell …
Circulating neutrophils activated by cancer cells and M2 macrophages promote gastric cancer progression during PD-1 antibody-based immunotherapy
C Zhou, L Guo, Q Cai, W ** strategies
L Zhao, J Hu, D Hu, H Wang, C Huang, R Luo… - Biomedicine & …, 2022 - Elsevier
Immunotherapy is now a mainstay in cancer treatments. Programmed cell death 1 (PD-
1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) therapies have …
1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) therapies have …
Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study
Y Long, W Yang, Y Bai, H Tao, F Zhang, L Wang… - Cancer Cell …, 2023 - Springer
Background Hyper progressive disease (HPD) describes the phenomenon that patients
can't benefit from immunotherapy but cause rapid tumor progression. HPD is a particular …
can't benefit from immunotherapy but cause rapid tumor progression. HPD is a particular …